MAP2K7 and neoplasm: This mechanism of ERBB-induced ERK activity was confirmed as BEZ235 treatment combined with HER2/3 antagonists (lapatinib or trastuzumab) or MEK inhibitor (selumetinib) led to decreased ERK activity and improved anti-tumour activity in vivo compared to BEZ235 treatment alone[60].